- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00602160
Therapeutic Effect of Chinese Herbal Medicine on Food Allergy (FAHF-2)
Investigation of the Efficacy of the Food Allergy Herbal Formula (FAHF-2TM) in Patients With Food Allergy - Phase II Trial
Study Overview
Detailed Description
To address our hypothesis, we propose the following aims:
Aim #1: To investigate the efficacy of FAHF-2TM for food allergy (in addition to current food allergen avoidance).
Aim #2: To characterize the immunomodulatory effects of FAHF-2TM on food allergic patients
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: JingJing Mei
- Phone Number: 212-241-6577
- Email: jingjing.mei@mssm.edu
Study Contact Backup
- Name: Sharon M Hamlin
- Phone Number: 212-241-1755
- Email: sharon.hamlin@mssm.edu
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States
- Recruiting
- University of Arkansas for Medical Sciences
-
Contact:
- June Staw
- Email: JAStraw@uams.edu
-
Contact:
- Christie Lynn
- Email: ChristieLynn@uams.edu
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Mount Sinai School Medicine
-
Principal Investigator:
- Julie Wang, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects ages 12 through 45 years of age and otherwise in good health as determined by medical history and physical examination
- History of allergy to peanut, tree nut, sesame, fish or shellfish as documented by a positive skin test and/or food allergen-specific IgE level.
- The subject agrees to participate in the study or the subject's parent or legal guardian is willing and able to give written informed consent, and the pediatric subject gives assent for participation in the study.
- Positive double-blind placebo controlled food challenge to peanut, tree nuts, sesame, fish, or shellfish.
- Females of childbearing potential must be inactive sexually or take effective birth control measures, as deemed appropriate by the investigator, for the duration of the study
Exclusion Criteria:
- History of life-threatening anaphylaxis to peanut, tree nut, sesame, fish or shellfish (involving hypotension or requiring mechanical ventilation)
- Allergy to corn
- Acute febrile illness (such as cold, flu, etc.) within one week before administration of study drug
- Any history of systemic disease that in the investigator's opinion would preclude the subject from participating in this study, e.g. autoimmune disease, neoplasms, HIV or hepatitis virus infection
- Allergic gastrointestinal disease (e.g. allergic eosinophilic esophagitis/gastroenteritis
- Abnormal hepatic function (ALT/AST and bilirubin >1.25 x upper limit of normal)
- Abnormal bone marrow function (WBC <4 x 103/mm3; platelets <100 x 103/mm3; hgb <11 g/dl)
- Abnormal renal function (BUN and creatinine >1.25 x upper limit of normal)
- Clinically significant abnormal electrocardiogram
Current uncontrolled moderate to severe asthma as defined by:
- FEV1 value <80% predicted or any clinical features of moderate or severe persistent asthma baseline severity (as defined by the 2007 NHLBI Guidelines) and greater than high daily doses of inhaled corticosteroids (as defined for children and adults using dosing tables from the 2007 NHLBI Guidelines).
- Use of steroid medications in the following manners: history of daily oral steroid dosing for >1 month during the past year, or burst or steroid course in the past 6 months, or >1 burst oral steroid course in the past year.
- Asthma requiring >1 hospitalization in the past year for asthma or >1 ED visit in the past 6 months for asthma.
- Participation in another experimental therapy study within 30 days of this study
- History of alcohol or drug abuse
- Currently taking antidepressant medication
- Pregnant or lactating female subjects. Females of childbearing potential will need a negative serum pregnancy test at screening to be considered for this study
- Use of omalizumab
- Use of beta blockers, ACE inhibitors, ARB, or calcium channel blockers, or history of ischemic heart disease
- Inability to discontinue use of antihistamines for skin testing or oral food challenges
- Inability to take the tablets
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
|
We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group. Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy. |
Active Comparator: 1
2 different dosages
|
We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group. Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety of FAHF-2
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
lab studies
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Julie Wang, M.D., Icahn School of Medicine at Mount Sinai
- Study Director: Xiu-Min Li, Icahn School of Medicine at Mount Sinai
Publications and helpful links
General Publications
- Wang Z, Wang ZZ, Geliebter J, Tiwari R, Li XM. Traditional Chinese medicine for food allergy and eczema. Ann Allergy Asthma Immunol. 2021 Jun;126(6):639-654. doi: 10.1016/j.anai.2020.12.002. Epub 2020 Dec 10.
- Noone S, Ross J, Sampson HA, Wang J. Epinephrine use in positive oral food challenges performed as a screening test for food allergy therapy trials. J Allergy Clin Immunol Pract. 2015 May-Jun;3(3):424-8. doi: 10.1016/j.jaip.2014.10.008. Epub 2015 Jan 13.
- Wang J, Jones SM, Pongracic JA, Song Y, Yang N, Sicherer SH, Makhija MM, Robison RG, Moshier E, Godbold J, Sampson HA, Li XM. Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy. J Allergy Clin Immunol. 2015 Oct;136(4):962-970.e1. doi: 10.1016/j.jaci.2015.04.029. Epub 2015 Jun 1.
- Song Y, Wang J, Leung N, Wang LX, Lisann L, Sicherer SH, Scurlock AM, Pesek R, Perry TT, Jones SM, Li XM. Correlations between basophil activation, allergen-specific IgE with outcome and severity of oral food challenges. Ann Allergy Asthma Immunol. 2015 Apr;114(4):319-26. doi: 10.1016/j.anai.2015.01.006.
- Yang N, Wang J, Liu C, Song Y, Zhang S, Zi J, Zhan J, Masilamani M, Cox A, Nowak-Wegrzyn A, Sampson H, Li XM. Berberine and limonin suppress IgE production by human B cells and peripheral blood mononuclear cells from food-allergic patients. Ann Allergy Asthma Immunol. 2014 Nov;113(5):556-564.e4. doi: 10.1016/j.anai.2014.07.021. Epub 2014 Aug 22.
- Patil SP, Wang J, Song Y, Noone S, Yang N, Wallenstein S, Sampson HA, Li XM. Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study. J Allergy Clin Immunol. 2011 Dec;128(6):1259-1265.e2. doi: 10.1016/j.jaci.2011.06.015. Epub 2011 Jul 26.
- Wang J, Patil SP, Yang N, Ko J, Lee J, Noone S, Sampson HA, Li XM. Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol. 2010 Jul;105(1):75-84. doi: 10.1016/j.anai.2010.05.005.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01AT001495-01A1 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Food Allergy
-
Vilnius UniversityEnrolling by invitationFood Allergy in Children | Food Allergy in InfantsLithuania
-
Vilnius UniversityEnrolling by invitationFood Allergy in Children | Food Allergy in InfantsLithuania
-
Assistance Publique Hopitaux De MarseilleUnknown
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustUnknownEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
-
Chinese University of Hong KongRecruiting
-
University Hospital, MontpellierUnknownFood Allergy Suspected | Food Allergy ProvedFrance
-
King's College LondonKing's College Hospital NHS Trust; University College London Hospitals; Cambridge... and other collaboratorsRecruitingEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
-
Stanford UniversityRecruitingFood Allergy | Food Allergy in ChildrenUnited States
-
Rhode Island HospitalCompletedFood Allergy in Children
-
Children's National Research InstituteNational Institute of Allergy and Infectious Diseases (NIAID); Northwestern... and other collaboratorsRecruiting
Clinical Trials on FAHF-2 (TM)
-
Tel-Aviv Sourasky Medical CenterAssaf-Harofeh Medical CenterCompleted
-
Xiu-Min LiUnknown
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); Atrium...CompletedVentral Hernia | AdhesionsUnited States
-
NephroSantNot yet recruitingKidney Transplant Failure and Rejection
-
Hamada AhmedCompleted
-
University Hospital TuebingenTerminatedApnea of Prematurity | Continuous Positive Airway Pressure | CPAP
-
Ivoclar Vivadent AGNot yet recruitingClass I or II Cavities in Premolars or Molars
-
Tufts UniversityBioElectronics CorporationTerminatedPostoperative Edema and PainUnited States
-
Boston UniversityNational Institute of Dental and Craniofacial Research (NIDCR)Not yet recruitingHIV Infections
-
BioTech Tools S.A.Completed